Bio-Techne Corp TECH
72.61
0.04
0.06%
as of 25 Sep
- Market cap
- $11.4B
- P/E
- 62.1×
Follow TECH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bio-Techne Corp (TECH) P/S ratio
As of 25 September 2026, Bio-Techne Corp (TECH) trades at a P/S ratio of 9.3×. Over the past ten years it has ranged from 5.6× (May 2026) to 22.4× (September 2021); the current reading is higher than 48% of that period. That is below the Biotechnology industry median of 11.5× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2026 | 9.1× | 36.47% |
| FY2025 | 6.6× | (31.80%) |
| FY2024 | 9.7× | (13.68%) |
| FY2023 | 11.3× | (8.20%) |
| FY2022 | 12.3× | (34.38%) |
| FY2021 | 18.7× | 37.22% |
| FY2020 | 13.7× | 23.32% |
| FY2019 | 11.1× | 28.17% |
| FY2018 | 8.6× | 10.93% |
| FY2017 | 7.8× | (7.33%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 9.1× | 34.41% |
| Mar 2026 | 6.7× | (10.51%) |
| Dec 2025 | 7.5× | 6.07% |
| Sep 2025 | 7.1× | 6.97% |
| 42 more quarters | Free account |
Against its own ten years
Low 5.6×
High 22.4×
Ten-year median
9.6×
Current reading's percentile
48
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| BMRN BioMarin Pharmaceutical Inc. compare | 3.4× |
| HALO Halozyme Therapeutics, Inc. compare | 8.0× |
| TECH Bio-Techne Corp | 9.3× |
| MDGL Madrigal Pharmaceuticals, Inc. compare | 11.7× |
| AXSM Axsome Therapeutics, Inc. compare | 13.0× |
| CORT Corcept Therapeutics Incorporated compare | 14.7× |
| BBIO BridgeBio Pharma, Inc. compare | 18.0× |
| KRYS Krystal Biotech, Inc. compare | 23.2× |
| SMMT Summit Therapeutics PLC compare | 17,230× |
| Biotechnology industry median | 11.5× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on TECH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement